
TOKYO -- Japanese pharmaceutical group Eisai has essentially given up on a prospective blockbuster Alzheimer's disease drug and will instead focus resources on developing a follow-up offering.
Failure to strike gold with Aduhelm prompts renewed focus on successor
TOKYO -- Japanese pharmaceutical group Eisai has essentially given up on a prospective blockbuster Alzheimer's disease drug and will instead focus resources on developing a follow-up offering.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.